Research programme: adenosine A2A receptor antagonists - Pharmacopeia

Drug Profile

Research programme: adenosine A2A receptor antagonists - Pharmacopeia

Alternative Names: PS-246518

Latest Information Update: 12 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Class
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 12 Oct 2009 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
  • 12 Oct 2009 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top